Q2 2026 Abbvie Inc Earnings Call Transcript

Jul 31, 2026 / 01:00 PM GMT

Transcript 8-K

Key Points

Positve

AbbVie Inc (ABBV) delivered another excellent quarter with total net revenues of nearly $17 billion, beating expectations by $300 million and reflecting robust sales growth of 10.2%.
Skyrizi continues to outperform, with global sales of $5.5 billion, up 24% operationally, and strong market share gains in psoriasis and IBD.
Rinvoq also exceeded expectations, with global sales of over $2.5 billion, up 23.7% operationally, and is on pace for 30% growth in gastroenterology this year.
The neuroscience portfolio delivered strong growth of approximately 20%, with Vraylar, Botox Therapeutic, Ubrelvy, and Qulipta all achieving double-digit sales growth.
The pipeline is advancing well, with multiple regulatory approvals (e.g., Decnopaz, Qulipta, Rinvoq in Europe) and promising data readouts expected in the second half of 2026.
The planned acquisition of Apogee Therapeutics is expected to bolster the immunology portfolio with differentiated assets in dermatology and respiratory diseases.
AbbVie Inc (ABBV) raised its full-year revenue guidance by $300 million, reflecting strong momentum and confidence in the business.

Negative

Humira global sales declined 36.1% operationally due to biosimilar competition, though this was in line with expectations.
Oncology revenues declined 2.4% operationally, with Imbruvica sales down 29.4% due to IRA pricing and competitive pressure.
Aesthetics revenues were slightly down 0.9% operationally, with Juvederm sales declining 6.6% due to continued headwinds in dermal filler markets.
The Apogee acquisition is expected to cause $0.14 of dilution to full-year adjusted EPS, partially offsetting underlying overperformance.
The company faces potential competitive pressures in psoriasis from new oral therapies like Icatide, though management sees no material impact so far.
The launch of Tavapadon in Parkinson's disease is expected to have a modest start due to formulary timing, which may limit near-term sales acceleration.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

ABBV.N - Abbvie Inc
Q2 2026 Abbvie Inc Earnings Call
Jul 31, 2026 / 01:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning and thank you for standing by.

Welcome to the Abbe second quarter 2026 earnings conference call.

All participants will be able to listen-only until the question-and-answer portion of this call.

You may ask a question by pressingar 1 on your phone.

Today's call is also being recorded.

If you have any objections, you may disconnect at this time.

I would now like to introduce Ms.

Liz Shay, Senior Vice President, Investor Relations.

Good morning and thanks for joining us.

Also on the call with me today, Rob Michael, Chairman and Chief Executive Officer, Jeff Stewart, executive Vice President, Chief Commercial Officer Ruppal Thacker, Executive Vice President,

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.